

alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

II. Comments

Interested persons may, at any time, submit written or electronic comments on the SECG entitled "Food Labeling; Serving Sizes; Reference Amount for Baking Powder, Baking Soda, Pectin" to the Dockets Management Branch (address above). Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments should be identified with the docket number found in brackets in the heading of this document. A copy of the document and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

III. Electronic Access

Copies of the SECG may also be viewed on a personal computer with access to the Internet. The Center for Food Safety and Applied Nutrition's home page includes the SECG and can be found at <http://www.cfsan.fda.gov/~dms/sodaguid.html>.

Dated: August 28, 2001.

Margaret M. Dotzel,

Associate Commissioner for Policy.

[FR Doc. 01-22481 Filed 9-6-01; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. 98N-1230, 96P-0418, and 97P-0197]

Small Entity Compliance Guide: "Food Labeling; Safe Handling Statements, Labeling of Shell Eggs; Refrigeration of Shell Eggs Held for Retail Distribution;" Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a small entity compliance guide (SECG) for a final rule that published in the **Federal Register** of December 5, 2000 (65 FR 76092), entitled "Food Labeling; Safe Handling Statements, Labeling of Shell Eggs; Refrigeration of Shell Eggs Held for Retail Distribution." The SECG is intended to set forth the requirements of that final rule in plain language and to

help small businesses understand the regulation.

DATES: Submit written or electronic comments on this SECG at any time.

ADDRESSES: Submit written comments concerning this SECG to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.fda.gov/dockets/ecomments>. Submit written requests for single copies of the SECG to the Office of Nutritional Products, Labeling and Dietary Supplements (HFS-800), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 200 C St., Washington, DC 20204, 202-205-4561. Send one self-adhesive address label to assist that office in processing your request. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the SECG.

FOR FURTHER INFORMATION CONTACT:

For the labeling provisions: Geraldine A. June, Center for Food Safety and Applied Nutrition (HFS-822), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-205-4168.

For refrigeration provisions: Nancy S. Bufano, Center for Food Safety and Applied Nutrition (HFS-306), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-401-2022.

SUPPLEMENTARY INFORMATION:

I. Background

To reduce the risk of illness and death from consumption of eggs contaminated with *Salmonella enteritidis* (SE), FDA published in the **Federal Register** of July 6, 1999 (64 FR 36492), a proposed rule requiring the labeling of shell eggs with a safe handling statement and the refrigeration of shell eggs at retail. FDA published the final rule in the **Federal Register** of December 5, 2000 (65 FR 76092).

FDA examined the economic implications of that final rule as required by the Regulatory Flexibility Act (5 U.S.C. 601-602) and determined that the final rule would have a significant economic impact on a substantial number of small entities.

In compliance with section 212 of the Small Business Regulatory Fairness Act (Public Law 104-121), FDA made available (via the Internet) a SECG stating in plain language the requirements of this regulation.

FDA is issuing this SECG as level 2 guidance consistent with FDA's good guidance practices regulation (21 CFR 10.115(c)(2)). The SECG represents the agency's current thinking on the subject.

It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

II. Comments

Interested persons may, at any time, submit written or electronic comments on the SECG entitled "Food Labeling; Safe Handling Statements, Labeling of Shell Eggs; Refrigeration of Shell Eggs Held for Retail Distribution" to the Dockets Management Branch (address above). Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments should be identified with the docket number found in brackets in the heading of this document. A copy of the document and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

III. Electronic Access

Copies of the SECG may also be viewed on a personal computer with access to the Internet. Center for Food Safety and Applied Nutrition's home page includes the SECG and can be found at <http://www.cfsan.fda.gov/~dms/eggsguid.html>.

Dated: August 28, 2001.

Margaret M. Dotzel,

Associate Commissioner for Policy.

[FR Doc. 01-22482 Filed 9-6-01; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director; Notice of Call for Applications for the Directors Council of Public Representatives (COPR)

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institutes of Health (NIH), the Federal government's primary agency for supporting and conducting medical research leading to the improvement in the nation's health, has established a relatively new national advisory council—the Directors Council of Public Representatives (COPR). The Chair of COPR is the Director of the National Institutes of Health. This notice describes the process for the selection of members of the COPR that NIH will use, as the original founding

members begin to complete their terms and begin the COPR rotation process.

DATES: The application deadline for the COPR is October 23, 2001; the notification of selection date is December 2001; the term start date is April 1, 2002; and the first COPR meeting date for new members is April 16, 2002.

FOR FURTHER INFORMATION CONTACT: NIH Council of Public Representatives (COPR), c/o Palladian Partners, Inc., 1010 Wayne Avenue, Suite 1200, Silver Spring, MD 20910, telephone (301) 650-8660, fax (301) 650-7172, e-mail COPR@palladianpartners.com. If you are interested in serving as a member of the COPR, please contact Palladian Partners, Inc. to have an application mailed to you or go on-line to www.nih.gov/about/publicliaison to access the COPR application instructions. If you have questions about your application or the submission process, please feel free to contact the staff working on this project by mail, telephone, fax, or e-mail, as indicated in the above information.

ADDRESS: Please mail your application to NIH Council of Public Representatives (COPR), c/o Palladian Partners, Inc., 1010 Wayne Avenue, Suite 1200, Silver Spring, MD 20910, telephone (301) 650-8660, fax (301) 650-7172, e-mail COPR@palladianpartners.com.

SUPPLEMENTARY INFORMATION: The Director of the National Institutes of Health (NIH) created the Director's Council of Public Representative (COPR) in 1999 as an important forum for information exchange between the public and the NIH at the highest level. The COPR consists up to 20 individuals who are selected from among the many diverse communities that benefit from, and have an interest in, NIH research, programs, and activities. The COPR allows representatives of the public to present issues, concerns, and viewpoints to the NIH Director and to take information from NIH back to the broader public. COPR terms are typically three-year terms.

The minimum eligibility criteria are that the applicant must:

- Have some interest in the work of NIH (such as being a patient or family member of a patient; a care giver, or a volunteer in the health or science arena; a scientist or student of science; a health communicator, educator or professional in the medical field, but certainly not limited to these examples).
- Be in a position (formally or informally) to communicate regularly with the broader public or segments of

the public about the activities of the COPR and the NIH.

- Commit to participating fully in activities of the COPR, including COPR meeting discussions and conference calls, and subcommittee and/or working group activities that will take time in addition to COPR meeting attendance twice a year.

Note: The NIH will cover travel expenses while on official government business as a COPR member.

In addition, COPR members—while participating in COPR activities—will have to agree to subordinate disease-specific or program-specific interests to broader, cross-cutting matters of importance to the NIH. COPR members will also need to agree to represent as broad a “public viewpoint” as possible and to at least keep the spirit of this goal at the forefront during all COPR discussions and activities.

Please contact Palladian Partners, Inc. to have an application mailed to you or go on-line to www.nih.gov/about/publicliaison to access the COPR application instructions. The NIH Director's COPR staff is located in the Office of Communications and Public Liaison, Office of the Director, National Institutes of Health. *The application deadline is Tuesday, October 23, 2001. We will not consider late nomination packages.*

After applications are screened for completeness, they will be reviewed and scored by external reviewers who are familiar with the responsibilities of the COPR. The NIH Director will make the final selection of candidates with the goal of creating a COPR that reflects the breadth and diversity of the publics interested in the NIH, taking into consideration many varied factors, including age, gender, culture, and geography. We expect that candidates will be selected in December 2001.

Thank you for your interest in the COPR. We look forward to receiving your application packet.

Dated: August 24, 2001.

Anne Thomas,

Associate Director for Communications, NIH.

[FR Doc. 01-22467 Filed 9-6-01; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice

is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 5452b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Development of Novel Imaging Technology (Phased Innovation award).

Date: October 1-2, 2001.

Time: 8 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda Holiday Inn, Versailles III, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Kenneth L. Bielat, PhD, Scientific Review Administrator, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, room 8043, Bethesda, MD 20892, (301) 496-7576.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: August 30, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-22462 Filed 9-6-01; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.